1 - Operation IDD Gene Team
50 years
rare disease

Rose F. Kennedy Intellectual and Developmental Disabilities Research Center


Founded 50 years ago, the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center has long been at the forefront of research on abnormal brain development in children. A key objective of the Rose F. Kennedy IDDRC leadership has been to enhance research collaborations between basic science investigators and our clinical partners in the hope of advancing understanding of neurodevelopmental disorders and enhancing translational studies designed to bring bench research discoveries to the bedside, in the form of new and innovative therapies.

Recent changes, in particular the Einstein-Montefiore merger, have been positive for the Center’s future as it enters its second half century.  For example, our closest clinical partner – the Children’s Evaluation and Rehabilitation Center (CERC) – is now revitalized under new leadership with its clinics fully consolidated in the Van Etten building, adjacent to Kennedy. This move has made available additional space in the Kennedy building, facilitating a planned expansion of the Neuroscience program through new recruitments. 

Further, continued integration with our Montefiore clinical partner, the Children’s Hospital at Montefiore (CHAM), has set the stage for ever-expanding translational studies, linking basic science expertise at Einstein with specific neurodevelopmental disorders seen at the CHAM clinics.  These clinics include those focused on Rett and Williams syndromes, Niemann-Pick, Tuberous Sclerosis, infantile/childhood seizures, and most recently 22q11.2DS, among others.



An integral part of Einstein’s RFK IDDRC’s outreach is our newsletter, which is published bi-annually and distributed both electronically and on paper.  read our newsletters > 

It often features notable ID related discoveries, interesting projects, opinion pieces, interviews and even human interest stories by doctors and researchers around campus.  learn more > 


Einstein’s RFK IDDRC is composed of five Cores: an Administrative Core (ADM), the Human Clinical Phenotyping Core (HCP), the Neurogenomics Core (NGEN), the Neural Cell Engineering & Imaging Core (NCEI), and the Animal Phenotyping Core (AP). learn more > 

The RFK IDDRC, through the ADM Core, brings nationally and internationally recognized speakers to Einstein Montefiore across a variety of venues. These include a seminar series, the annual Isabelle Rapin Conference, and Rare Disease Day. learn more > 


A Message From the Director

Dr Steven Walkley

Steven U. Walkley, D.V.M., Ph.D.

One could readily, and I believe successfully, argue that the topic of fetal and early postnatal development of the human brain is one of the most important, yet least studied areas of Neuroscience and Pediatrics. The developing brain, both before and after birth, is sensitive to many insults – read more... 

2019 IDDRC Pilot Project Announcement


Solving Rett Syndrome
Read more 

2018 IDDRC Pilot & Feasibility Awards
Click here for Award Recipients 

IDDRC Reporter
Click here for Report  

Past funding announcements 

Click here to log in

Research Round-Up

Elective ServiceDr. Susan Band Horwitz was elected to serve as one of the members of the AACR Nominating Committee for the 2012 to 2014 term. Founded in 1907, the AACR (American Association for Cancer Research), is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. Its membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. Dr. Horwitz is distinguished university professor and co-chair of molecular pharmacology at Einstein, as well as associate director for therapeutics for the Albert Einstein Cancer Center and the Rose C. Falkenstein Professor of Cancer Research. She also is an AACR past president and currently serves as a member on the Council of Scientific Advisors.

Good Reading Dr. U. Thomas Meier was awarded a $1.2 million grant over four years by the National Institute of General Medical Sciences to study how cells assemble small nucleolar RNA-protein complexes that function in the modification of ribosomal and other RNAs, thereby fine-tuning protein synthesis and pre-messenger RNA processing.  Dr. Meier’s laboratory will use novel approaches to shed light on these basic cellular processes, thus providing the foundation for understanding what goes wrong in certain genetic diseases and cancers.  Dr. Meier is professor of anatomy and structural biology.

read more